Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inpegsomatropin - Xiamen Amoytop Biotech

Next Previous
Drug Profile

Inpegsomatropin - Xiamen Amoytop Biotech

Alternative Names: Y-shape pegylated somatropin - Xiamen Amoytop Biotech; YPEG-rhGH; YPEG-somatropin - Xiamen Amoytop Biotech

Latest Information Update: 09 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xiamen Amoytop Biotech
  • Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
  • Mechanism of Action Human growth hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Short stature; Turner's syndrome
  • Phase II/III Somatotropin deficiency

Most Recent Events

  • 08 Jul 2026 Phase-III clinical trials in Turner's syndrome (SC) prior to July 2026 (Xiamen Amoytop Biotech pipeline, July 2026)
  • 10 Jun 2026 Phase-II clinical trials in Somatotropin deficiency in China (SC) (NCT07551804)
  • 02 Jun 2026 Xiamen Amoytop Biotech plans a phase III trial for Turner syndrome (In children) in China (SC, Injection) in June 2026 (NCT07614152)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top